Almac Group Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
52
About the Report
About the Report
Summary
Almac Group Ltd (Almac) is a contract development and manufacturing organization provides integrated services to pharmaceutical and biotechnology companies. The company offers a comprehensive range of services across the lifecycle of biopharmaceutical products which extend from research through pharmaceutical and clinical development to commercialization of products. Its services portfolio encompass diagnostics and biomarker development; clinical technologies; API (Active Pharmaceutical Ingriendient) services and chemical development; pharmaceutical development; analytical services; clinical services; and commercial services. The company operates through its subsidiaries in California, North Carolina and Pennsylvania in the US; and Singapore. Almac is headquartered in Craigavon, Northern Ireland, the UK.
Almac Group Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Almac Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Almac Group Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Galen Acquires US Rights to ADASUVE from Alexza Pharma 12
Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 13
Almac Acquires Noack N 623 Blister Packaging Line From Romaco Pharma 14
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 15
Partnerships 17
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 17
Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 19
McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 20
Elasmogen and Almac Discovery Enter into Co-Development Agreement 21
Almac Discovery Enters Into Agreement With Queen's University Belfast For Drug Discovery 22
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 24
Almac Enters Into Distribution Agreement With Affymetrix For Xcel Array 25
Licensing Agreements 26
Debiopharm International Enters into Licensing Agreement with Almac Discovery 26
Genentech Enters into Licensing Agreement with Almac Discovery 27
Galen Enters Into Licensing Agreement With Medical Developments International For Penthrox 28
Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 29
Acquisition 30
Almac Acquires 100% Stake in Bioclin Research Laboratories 30
Almac Group Acquires Arran Chemical 31
Almac Group Ltd-Key Competitors 32
Almac Group Ltd-Key Employees 33
Almac Group Ltd-Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 37
Strategy And Business Planning 37
Oct 10, 2018: Almac Group invests to expand its existing North Carolina Facility 37
Feb 28, 2018: Almac Group Expands with Opening of GBP20 million Cold Chain Facility 38
Jan 26, 2018: Almac Group Announces Further Global Expansion as it Secures New Premises in Republic of Ireland 39
Jan 24, 2018: Almac Group Launches Bespoke Elemental Impurities Laboratory 40
Jan 09, 2017: Almac Group Launches Almac Clinical University 41
Financial Announcements 42
Jun 04, 2018: Almac Group turnover surpasses GBP500 million for first time 42
Corporate Communications 43
Aug 27, 2018: Almac Group appoints new site head for Charnwood Campus, Loughborough, UK 43
Legal and Regulatory 44
Oct 02, 2018: Almac Group announces successful HPRA inspection at its European campus 44
Jul 27, 2018: Almac Group launches GMP high throughput peptide manufacturing service 45
Jan 18, 2018: Almac Group announces further expansion at its European Campus in Dundalk 46
Oct 23, 2017: Almac Group Announces Successful MHRA Inspection at Charnwood Facilities 47
Product News 48
Jan 30, 2017: Almac Group Launches Next Generation Temperature Management Software 48
Other Significant Developments 49
Oct 09, 2018: Arran Chemical Company Completes Stage II of its Strategic Plan ADAPT 49
Jul 16, 2018: Almac Group Invests in NMR Equipment to Enhance Existing Analytical Services Capability 50
Jun 07, 2017: Almac Group Reports Pre-tax Profits of GBP27M 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Figure
List of Figures
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Almac Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Almac Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Almac Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Almac Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Almac Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Galen Acquires US Rights to ADASUVE from Alexza Pharma 12
Galen Acquires US Rights For Synera From Nuvo Research For USD14.5 Million 13
Almac Acquires Noack N 623 Blister Packaging Line From Romaco Pharma 14
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 15
Genomic Health Enters Into In-Licensing Agreement With Almac To Develop And Commercialize Anthracycline Chemotherapy Benefit Test 17
Almac Discovery and Royal College of Surgeons in Ireland Enter into Research Agreement 19
McClay Foundation, Almac Discovery and University of Ulster Enter into Research Agreement 20
Elasmogen and Almac Discovery Enter into Co-Development Agreement 21
Almac Discovery Enters Into Agreement With Queen's University Belfast For Drug Discovery 22
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 24
Almac Enters Into Distribution Agreement With Affymetrix For Xcel Array 25
Debiopharm International Enters into Licensing Agreement with Almac Discovery 26
Genentech Enters into Licensing Agreement with Almac Discovery 27
Galen Enters Into Licensing Agreement With Medical Developments International For Penthrox 28
Almac Discovery Enters Into Licensing Agreement With Shin Poong Pharma For ALM201 29
Almac Acquires 100% Stake in Bioclin Research Laboratories 30
Almac Group Acquires Arran Chemical 31
Almac Group Ltd, Key Competitors 32
Almac Group Ltd, Key Employees 33
Almac Group Ltd, Other Locations 34
Almac Group Ltd, Subsidiaries 34
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.